Apply for Grants
The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cognition Biomarkers, 2014miRNA Markers of Cognition
Objective/Rationale:
In previous MJFF-funded research, these researchers identified four promising microRNAs (which regulate gene expression) associated with cognitive status. They profiled the miRNAs... -
Improved Biomarkers and Clinical Outcome Measures, 2019Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline
Study Rationale:
Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Validating the Montreal Cognitive Assessment for the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Dementia affects up to 80 percent of Parkinson’s disease patients, and the prevalence of other dementias including Alzheimer’s disease is high in this age group. A need exists for... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Cognitive Decline in Parkinson's Disease
Objective/Rationale:
There are many studies on cognitive and behavioral alterations in Parkinson’s disease, but each of these investigations brought only a small piece of a large puzzle. Consequently... -
Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022Multiculturalism, Reported Cognitive Complaints and Predictors of Cognitive Decline Following Deep Brain Stimulation
Study Rationale: Cognitive decline is common in people with Parkinson’s disease (PD), and changes in thinking and performance on objective cognitive tests reported by individuals and their family are...
-
Repositioning Drugs for PD, 2012Atomoxetine for Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Parkinson’s disease (PD) causes well known motor symptoms of tremor, slowness and stiffness, but also leads to cognitive impairment. Research has shown that early loss of cells in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.